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Abstract
The sex hormone estrogen plays critical roles in reproductive and sexual  
development. It regulates the expression and activity of key signaling molecules 
critical in various cellular signaling pathways. These signals are mediated by its 
binding to estrogen receptors alpha (ERα) and beta (ERβ). ERα has been shown to 
greatly participate in extranuclear signaling, inducing tumorogenesis and breast 
cancer metastasis. Small molecules from plants are reported with better selectivity 
toward tumorigenic cells with negligible toxicity when compared to their synthetic 
counterpart. The molecules used in this study were first probed for their drug-
likeness and their pharmacokinetic profile was elucidated before docking them to 
the ligand binding domain of the human ERα followed by a post docking prime 
analysis. All tested molecules had good drug-like and pharmacokinetic properties 
when compared to about 95% of orally available drugs as predicted by qikprop. The 
docking results revealed a strong binding interaction with ERα, influenced mostly 
by the vicinal diol groups of the studied molecules. These resulted in a conforma-
tional change, inducing receptor dimerization and altering the interactions of the 
sex hormone with other proteins. The studied ligands are promising in strongly 
inhibiting the binding of estrogen to ERα, thus limiting its extranuclear signaling.
Keywords: sex hormones, human estrogen receptor alpha (hERα), molecular 
docking, pharmacokinetics, extracellular signaling, breast cancer
1. Introduction
Estrogen plays an important role in mammary gland development and has 
been implicated in the initiation and progression of breast cancer [1]. There are 
two major receptors with which this sex hormone binds to mediate its biological 
activities. These receptors are estrogen receptors, alpha and beta (ERα and ERβ). 
ERα is present mainly in mammary gland, uterus, ovary (thecal cells), bone, male 
reproductive organs (testes and epididymis), prostate (stroma), liver, and adipose 
tissue. By contrast, ERβ is found mainly in the prostate (epithelium), bladder, ovary 
(granulosa cells), colon, adipose tissue, and immune system. Both subtypes are 
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markedly expressed in the cardiovascular and central nervous systems. The alpha 
subtype has a more prominent role on the mammary gland and uterus, as well as on 
the preservation of skeletal homeostasis and the regulation of metabolism. The beta 
subtype seems to have a more profound effect on the central nervous and immune 
systems [2]. In terms of sequence homology, the ERβ shows a high homology to ERα 
in the DBD (more than 95% amino acid identity) and in the LBD (~55% amino acid 
identity) [3, 4]. However, the NTD of ERβ is shorter than that of ERα with a very 
poor sequence homology of only ~15% compared to that of ERα (Figure 1A and B).
The major ER subtype is the ERα which has been reported in about 70% of 
breast cancer cases [7]. In addition to the well-studied nuclear functions of ERα, 
it also participates in extranuclear signaling which involve growth factor signaling 
components, adaptor molecules and the stimulation of cytosolic kinases [8]. ERα 
extranuclear pathways have the potential to activate gene transcription, modulate 
cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. 
Inhibition of ERα extranuclear actions is, thus, a promising strategy to curb breast 
tumor progression and may be useful in preventing ERα positive metastasis.
Commonly used endocrine therapies include: selective estrogen receptor modu-
lators (such as tamoxifen, raloxifene, toremifene), aromatase inhibitors (such as 
anastrozole, letrozole and exemstane) and selective estrogen receptor downregulators 
(such as fulvestrant). Unfortunately, tumor cells readily develop resistance to these 
therapies in a progressive manner, a major obstacle limiting the success of breast 
cancer treatment. Resiatance may be de novo or acquired and has been shown to be 
influenced by complicated crosstalks. These resistance to available therapies combined 
with their undue toxicities provoke the search into small molecules from plant, deemed 
Figure 1. 
Sequence organization of estrogen receptors, ERα and ERβ (A and B) and the 3D structures of studied ligands 
(C). (A) Shows different domains highlighted in different colors: NTD = amino terminal domain (in red); 
DBD = DNA binding domain (in green); hinge region in blue; LBD = ligand-binding domain (in yellow);  
F region located towards the C-terminal end (in gray). Amino acid sequence position is given for each domain. 
(B) Shows 3-dimensional structures of ERα (left) and ERβ (right) bound to estradiol (PDB structures 1A52 [5] 
and 3OLS [6]. (C) Shows 3D structures of all studied ligands.
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to be less toxic [9] which can destabilize and/or downregulate the commonly impli-
cated estrogen receptor (hERα) in a bid to intercept the complicated crosstalks [10].
There are critical steps in the development of effective pharmacotherapy, with 
many phases and stages within each of them. The first step which is discovery and 
development involve target discovery and validation, lead refinement as well as 
preclinical development. This is often followed by preclinical research, which tests the 
new drug on non-human subjects for efficacy, toxicity, and pharmacokinetic (PK) 
information with unrestricted dosages. Preclinical research involves in vivo, in vitro, ex 
vivo and in silico assays. The next step is the clinical development and involves clinical 
trials and volunteer studies to fine-tune the drug for human use before submitting for 
a holistic FDA review. The final critical step is the FDA post-market safety monitor-
ing. It cost so much before a suitable drug candidate finally gets to the market and 
failure which frequently taunts the process can better be imagined than experienced.
Several promising drug candidates have failed to reach the market due to their 
poor pharmacokinetic properties. Many compounds with promising pre-clinical 
medicinal properties may not even stand a chance of being tried because of their 
non-drug-likeness except after rigorous improvement which may end up increas-
ing toxicity. Today, with the advancement in medical and pharmaceutical sciences, 
computational techniques has proven useful for early prediction of the absorption, 
distribution, metabolism, excretion and toxicity (ADMET) profile of potential drug 
molecules before subjecting them to rigorous pre-clinical and clinical testings [11]. In 
silico approaches like molecular docking has been successfully applied in the screen-
ing and selection of potent drugs in the treatment of diseases [12]. These techniques 
are now extensively employed by pharmaceutical companies for screening for lead 
compounds to facilitate entrance of potential drug molecules with good drug-like-
properties into the market while eliminating molecules with poor profile [13]. The 
purpose of this study was to investigate the pharmacokinetic properties and drug-
likeness of the selected small molecules and investigate its inhibitory potential to the 
ERα, with the view of mitigating this sex hormone’s receptor extranuclear signaling.
2. Materials and methods
2.1 Computer hardware and software
The molecular docking simulation was performed on the Lenovo Precision 
workstation 6.1.7600 running Intel® Core™ i5 Duo Processor, 4.0GB RAM, 
436 GB hard disk and AMD Radeon graphics card (Lenovo PC HK Limited, China). 
The 3D structures of the small molecules were obtained from the National Centre 
for Biotechnology Information, Pubchem database www.ncbi.nlm. nih.gov/
pccompound) in SDF format and prepared with Maestro, using ligprep version 
3.6 (LigPrep 2015). The solution x-ray crystal structure of the human ERα (3UUD, 
1.60 Å resolution) was retrieved from the protein databank (www.rcsb.org) using 
Discovery Studio visualizer 4.5 (Accelryls, USA). Protein-ligand docking simula-
tion was performed using the Schrodinger molecular docking suite version 2018-4.
2.2 Preparation of ligands and protein
The ligands were prepared using LigPrep, a utility of Schrodinger software suit 
that combines tools for generating 3D structures from 1D (Smiles) and 2D (SDF) 
representation. Molecular mechanics force fields, optimized potentials for liquid 
simulations-2005 (OPLS_2005) with default settings were employed for the ligand 
minimization and the ligands were thereafter filtered for computational studies.
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The crystal structure of hERα (3UUD) was prepared using Schrodinger protein 
preparation wizard tool (Glide), which performed the following steps: assigning of 
bond orders, addition of hydrogens, optimization of hydrogen bonds by flipping 
amino side chains, correction of charges and minimization of the protein complex. 
All the bound water molecules, ligands and cofactors were removed (preprocess) 
from the protein and the output file was saved in maestro format. The idle side 
chains were neutralized before restrained minimization of co-crystallized complex, 
which reoriented side chain hydroxyl groups and alleviated potential steric clashes. 
The complex obtained was minimized using OPLS_2005 force field with Polack-
Ribiere Conjugate Gradient (PRCG) algorithm. The minimization was terminated 
when the energy gradient converged below 0.05 kcal/mol [14].
2.3 Prediction of pharmacokinetic properties and drug-likeness
The molecular weight, number of hydrogen bond donor, number of hydrogen 
bond acceptor and octanol–water partition coefficients were used to verify the com-
pounds adherence to Lipinski’s rule of five which qualifies their drug-likeness. To 
nominate drug candidates, certain pharmacokinetics descriptors that portray their 
drug-likeness [15] were investigated using the QikProp module of the Schrodinger 
Suite, a program designed by Professor William L. Jorgensen [16]. In addition to 
predicting physically significant and pharmaceutically relevant molecular descrip-
tors, QikProp also provides ranges for comparing predicted descriptors of each 
compound with those of 95% of drugs known for oral use. The pharmacokinetic 
descriptors evaluated were: molecular weight(Mwt), total solvent accessible surface 
area (SASA), Donor hydrogen bond (DonorHB), number of acceptable hydrogen 
bond (Accept HB), predicted octanol/water partition coefficient (QPlogPo/w), 
predicted aqueous solubility (QPlogS), predicted apparent Caco-2 cell permeability 
(QPPCaco), predicted brain/blood partition coefficient (QPlogBB), number of 
likely metabolic reactions(#metab), human oral absorption, van der Waals surface 
area of polar nitrogen and oxygen atoms (PSA) and prediction of plasma protein 
binding(Khsa). Cytochrome P450 inhibitory promiscuity and inhibition of the 
human either-a-go-go-ralted gene was also accessed via admerSAR web server. The 
analysis in the present study was run on QikProp at the normal processing mode 
with default settings (QikProp 2018). The prepared ligands were used as input 
structures and their pharmacokinetics profiles with respect to properties shared 
by 95% of drugs known for oral use were evaluated. Compliance or deviant of the 
tested potential drug candidates to the Lipinski’s rule of five was also examined 
before they were considered drug-like [17].
2.4 Docking studies
Docking studies were carried out using Glide XP of the Schrodinger Suite 
(Maestro Version 11.8 and Glide version 8.0, 2018-4) docking program following 
the reported standard procedures [18]. Each ligand was individually docked onto 
the LBD of the hERα using Glide extra precision (XP) mode. In the course of the 
docking, several binding poses were generated for each ligand and the best binding 
pose was selected at the end of the docking process.
2.5  Calculation of ligand free energy of binding with the hERα using the 
MM-GBSA approach prime energy analysis
The Prime MM-GBSA or ‘molecular mechanics energies combined with the 
generalized Born and surface area continuum solvation’ approach was used in the 
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post-assessment of free energy of binding of ligands-hERα complex [19]. This 
approach uses the OPLS_2005 all-atom force field for protein residues, ligands and 
cofactors [20, 21]. The input structures for these calculations were taken from a 
pose viewer file Glide output after the docking study.
The following descriptors were generated by the prime MM-GBSA approach:
1. MM-GBSA_∆G_bind (ligand binding energy ( bindG∆ ))
2. MM-GBSA_E_complex (energy of the complex ( complexG ))
3. MM-GBSA_E_protein (energy of the receptor without the ligand ( proteinG )) and
4. MM-GBSA_E_ligand (energy of the unbound ligand ( ligandG )).
The total free energy ( bind)∆G  of binding is expressed as:
 ( )–bind complex protein ligandG G G G∆ = +  (1)
The other parameters for the complex were:
1. Prime Coulomb energy ( bindG∆ coulomb)
2. Prime Van der Waals energy ( bindG∆ vdW)
3. Prime Hydrogen Bond ( bindG∆  H-bond)
The MM-GBSA scoring and experimental binding affinity data of the binding 
site for the molecules on hERα were recorded.
3. Results
3.1 The structures of the protein and studied ligands
The 3D structures of the studied ligands are as shown in Figure 1c. Complete 
X-ray structure of of the hERα (Figure 2A) and its binding amino acids depicted 
with green sticks are as shown in Figure 2B above.
Figure 2. 
(A) Complete X-ray structure of hERα shown as ribbon (B) active amino acids shown in green sticks at the 










Compounds MWA SASAB Donor HBC AcceptHbD QPlogPo/wE QPlogSF QPPCacoG QPlog BBH #metabI Human Oral 
Absorption 
(%)J
PSAK KHSAL Rule of
FiveM
Myricetin 318.239 522.36 5 6 −0.279 −2.557 7.666 −2.817 6 28.186 161.312 −0.493 1
Estradiol 272.386 510.237 2 2.45 4.00 −4.672 1221.948 −0.366 4 100 43.693 0.438 0
Catechin 290.272 513.734 5 5.45 0.466 −2.648 53.247 −1.904 7 60.572 115.499 −0.42 0
Pinobanksin 272.257 492.522 2 4.95 1.472 −3.088 211.884 −1.171 5 77.194 97.055 −1.68 0
Pinocembrin 256.257 486.989 1 3.25 2.383 −3.684 431.998 −0.83 5 88.067 77.67 0.136 0
Gelangin 270.241 488.021 2 3.75 1.791 −3.296 193.621 −1.221 3 78.363 95.964 −0.041 0
Pinostrobin 270.284 509.441 0 3.25 3.084 −3.844 1427.908 −0.351 5 100 63.409 0.181 0
Tamoxifen 371.521 725.086 0 2.75 6.525 −5.833 2203.131 0.366 3 100 11.493 −7.4 1
Range for 95% known drugs: A (Molecular weight = 130.0–725.0); B (Total solvent accessible surface area = 300.0–1000.0); C (Donor HB = 0.0–6.0); D (Accept HB = 2.0–20.0); E (Predicted 
octanol/water partition coefficient = −2.0-6.5); F (Predicted aqueous solubility = −6.5-0.5); G (Predicted apparent Caco-2 cell permeability = < 25 poor, >500 great); H (Predicted brain/blood 
partition coefficient = −3.0-1.2); I (Number of likely metabolic reactions = 1–8); J (% Human oral absorption = > 80% → High, < 25% → Poor); K (van der Waals surface area of polar nitrogen and 
oxygen atoms = 7.0–200.0); L (Human serum albumin = −1.5-1.5); M (Number of violations of Lipinskis Rule of Five; mol MW < 500, QPlogPo/w < 5, donor HB ≤ 5, accpt HB ≤10. Compounds that 
satisfy these rules are considered drug-like.
Table 1. 
Pharmacokinetic properties of studied ligands.
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3.2 Pharmacokinetic profile of tested ligands
All the tested compounds obeyed the Lipinski’s rule of five (see Table 1). From 
the result of cell permeability using the caco-2 model, estradiol, pinostrobin and 
tamoxifen showed a great permeability prediction while moderate permeation 
was observed with catechin, pinobankskin, pinocembrin and gelagin (Table 1). 
Myrecetin, on the other hand showed very poor predicted cell permeability. All 
studied ligands had good predicted aqueous solubility (log S), and their blood brain 
barrier prediction, surface area of solvent absorption, predicted number of pos-
sible metabolic transformations, as well as polar surface area was within the range 
set for orally available drugs (see Table 1). For the prediction of plasma protein 
binding, tamoxifen had a score of −7.4, which was not within the stipulated range of 
−1.5-1.5, howbeit, other ligands had a good plasma protein prediction. Pinostrobin, 
tamoxifen, estradiol and pinocembrin had high predicted oral bioavailabilities 
Figure 3. 
3D and 2D molecular interaction of gelagin (a, a1), myrecetin (b, b1) and pinobanksin (c, c1) with crucial 
amino acids at the ligand binding domain of hERα.
Reproductive Hormones
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while moderate oral bioavailabilities were observed with Gelagin, pinobanksin, and 
catechin. Myricetin had the least predicted human oral availability.
3.3 Protein-ligand interactions
Structurally, each of the studied ligand contained the basic flavone skeleton 
linked by a three-carbon chain forming a closed pyran ring. Considering hydrogen 
bond interactions of the studied molecules with active amino acids of the estrogen 
receptor, from the results, the 7-OH of gelagin (Figure 3 (a & a1)) formed one 
hydrogen bond with Glycin 521 at a distance of 1.89 Ǻ and a π-cation interactions 
with phenylalnine 404 and histidine 524. The 31- OH and 41- OH groups of myricetin 
each established 1H bond with glutamic acid 353 residue at distances of 1.59 Ǻ and 
1.74 Ǻ respectively. A firm interaction was also observed with Arginine 394 by the 
41- OH of myricetin at distances of 1.97 Ǻ and 2.26 Ǻ. The 8- OH of myricetin also 
established 1H bond with histidine 524 and glycin 521 at 1.90 Ǻ. There was also a 
π-interaction of this ligand with phenylalanine 404 and histidine 524 (Figure 3 (b 
& b1)). In Figure 3 (c & c1) 1H bond each was established between the 8- OH of 
Figure 4. 
3D and 2D molecular interaction of pinostrobin (d, d1), pinocembrin (e, e1) and with crucial amino acids at 
the ligand binding domain of hERα.
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pinobankskin and Glycine 521 and Methionine 388 at distances of 1.78 Ǻ and 1.89 Ǻ 
respectively. A pi-pi interaction was also observed between the ligand and phenyala-
nine 404 as well as histidine 524. A pi-pi interaction was formed between pinostrobin 
and phenyalanine 404 of the hERα while its 8- OH group formed one hydrogen 
bond with glycine 521 at 1.78Ǻ (Figure 4 (d & d1)). Pinocembrin (Figure 4 (e & e1)) 
established a pi-cation interaction with phenylalanine 404 and histidine 524 while 
its 5-OH group formed 1H bond with leucine 387 at 1.89 Ǻ. A strong interaction was 
observed between its 8- OH group and glutamate 353 at 1.57 Ǻ. Tamoxifen, on the 
other hand, established 1H bond with Arginine 394 at 2.34 Ǻ and a pi-cation interac-
tion with phenylalanine 404 and histidine while estradiol, the native ligand had  
1H bond each with glutamate 353 and histidine 524 at distances of 1.80Ǻ and 2.04Ǻ 
respectively (Figure 5 (f and g)). A pi-pi interaction was also observed with histidine 
524 and phenylalanine 404.
3.4 Post docking prime analysis of studied ligands
From the prime energy calculations, the quantity of free energy of binding, 
bindG∆  calculated from Eq. (1) was in the following order: estradiol>myricetin>cate
chin>gelagin>pinobankskin>pinocembrin>pinostrobin (Figure 6). Other compo-
nents which contributed to the electrostatic interaction like the quantity of prime 
coulomb energy of the complex ( bindG∆ coulomb), prime van der Waals energy of 
the complex interaction ( bindG∆ vdW), the quantity of prime hydrogen bonding 
interaction are as presented in Table 2.
Figure 5. 
Molecular interaction of tamoxifen (f) and estradiol (g) with crucial amino acids at the ligand binding 
domain of hERα.
Figure 6. 




Estrogen, a major sex hormone plays an important role in mammary gland 
development and in the initiation and progression of breast cancer. The activities 
of estrogen are being mediated via its unique receptors, ERα and ERβ. The former 
(ERα), is the major ER subtype in the mammary epithelium. Upon activation of the 
hERα following its occupation, the receptor translocates to the nucleus, where it inter-
acts with the target gene promoters of estrogen response element to mediate nuclear 
as well as extranuclear signaling [8, 22]. This results in the regulation of numerous 
critical cellular processes and is implicated in the dilemma of breast cancer. Research 
reveals that ERα extranuclear pathways, which are incited by undue activation of 
hERα have the potential to activate gene transcription, modulate cytoskeleton, and 
promote tumor cell proliferation, survival, as well as metastasis. The expression of 
extranuclear components ERα is deregulated in tumors, thus, serving as an impor-
tant target for tumorigenic and metastatic control. Resistance to available endocrine 
therapies provokes metastasis and frustrates the management of this disease, thus, 
reducing the survival rate of patients bearing such tumors [23, 24]. This study evalu-
ated the inhibitory potential of the reported small molecules from nature against 
hERα in a bid to suppress its downstream signaling.
The high attrition rate of new chemical entities has been attributed majorly to 
poor pharmacokinetic profile [25]. The reported ligands have been shown to be 
drug-like, having satisfied the Lipinski’s rule of five [17] and also possess pharma-
ceutically relevant properties when compared to 95% of orally available drugs [16]. 
Hence, these compounds are fit in their current state to be developed into drugs 
without any modification/optimization except myricetin. Myricetin showed poor 
human absorption when examining its caco-2 permeability and human oral bio-
availability. This observed poor absorption of myricetin will retard how quickly and 
how much of it will reach its intended target (site) of action. Hence, this phytocon-
stituent will require optimization to prevent its failure in the market [26].
Aqueous solubilities and human oral absorption are critical for oral dosage 
formulation and their in silico prediction had been reported to correlate well with in 
vivo bioavailabilities [27]. According to Bergström 2005 [28], aqueous solubility and 
intestinal permeability are the two rate-limiting barriers for oral drug absorption 
while the therapeutic potential of a drug is dependent on its bioavailabilty [29]. All 
the tested compounds showed positive human intestinal absorption.
Following absorption, the drug or intended drug molecule will circulate through 
the body, permeating different tissues at varying speed, depending on its ability to 





ΔGbind lipophilic ΔGbind vdW
Myricetin −34.6588 −2.2352 −34.5106 −33.2389
Estradiol −20.0967 −2.04811 −66.6318 −47.0585
Catechin −28.643 −2.94963 −39.0821 −23.3243
Pinobanksin −13.6085 −0.092 −36.3471 −35.5581
Pinocembrin −14.97 −0.99013 −36.5651 −26.7548
Gelangin −9.44593 −0.16506 −34.4349 −37.5343
Pinostrobin −5.32169 −0.2392 −41.3577 −25.8845
Table 2. 
Output properties from a prime MM-GBSA calculation for the studied ligands.
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they get tightly bound to proteins circulating in the blood. Others quickly leave the 
bloodstream and enter other tissues because they are less tightly bound to blood 
proteins. There are also possibilities for virtually all molecules of a drug to bind 
tightly to blood proteins. It is worthy of note that irrespective of how promising a 
drug molecule is, its efficacy will be lost if its maximum concentration gets bound 
to plasma proteins. This will eventually result in the decrease of effective concentra-
tion at the site of action in the tissues, as only unbound drugs can be available for 
pharmacological activity [14]. To predict the distribution of the studied ligands, 
their plasma protein binding and blood brain barrier penetration was investigated. 
Unlike all compounds which showed good distribution, tamoxifen, however, did 
not comply within the range, indicating its high potential binding to albumin. 
This observation was in line with previous report on the high binding affinity of 
tamoxifen to serum albumin [30, 31]. Considering blood brain barrier permeation, 
studied compounds showed no tendency of crossing it. This can be explained by the 
lipophobicity of the studied ligands. It therefore means that they will not provoke 
any significant central effect that will result in subsequent toxicity.
Another key parameter is metabolism, which is responsible for the elimination 
of drugs from the body. Through metabolism, drug molecules can also be converted 
into pharmacologically more active substrates. In this study, the molecules were 
investigated to predict their possible number of biotransformation which could 
point to potential toxicities [32, 33]. From the results, all the compounds complied 
with the range of metabolic reactions displayed by 95% of orally available drugs. 
Some of the phytoligands were predicted to possess cytochrome P450 (CYP 450) 
inhibitory promiscuity, revealing their capacity to bind to and decrease or diminish 
the activity of multiple different CYP 450 isoform enzymes [34]. It should be noted 
that all the molecular descriptors predicted by qikprop are exclusively for drugs 
intended for oral delivery. This route of drug administration is still the most pre-
ferred route for new chemical entities (NCEs) in spite of advances in drug delivery 
methods. Oral mode of drug delivery is convenient, cheap and has high patient 
compliance. Using the in silico prediction of pharmacokinetics-related profile of 
intended drug molecules helps to reduce the rate of attrition of new chemical enti-
ties in clinical trial and reduces the cost of bringing a candidate drug to the market.
In modern drug discovery, molecular docking has been gainfully employed in 
the screening and selection of potent inhibitors [35] especially when the anticancer 
target has been identified. In this study, structurally similar phytochemicals from 
plant origin were used to probe for binding interaction with the human estrogen 
receptor α. As a prerequisite, the molecular docking protocol was validated. From 
the results, the redocked binding pose of the native ligand was correctly reproduced 
within the root mean square tolerance of 2 Å. This distance is an indication of an 
appropriate reproducibility for a docking experiment [36, 37]. This reproduc-
ibility of the redocked native ligand was similar to the poses of the docking control 
reported by Hocker et al. (2013) [38].
Inhibiting hERα is a valid approach in ameliorating the progression of breast 
cancer. This study revealed strong binding affinities of the investigated compounds 
to the hERα. This interaction which was depicted in their free energy of binding 
was greatly influenced by the vicinal diol groups. The residues of estrogen receptor 
which partook in this binding interaction was earlier reported to play critical roles 
in the inhibition of the ligand binding domain of the hERα [39, 40]. The interaction 
of these compounds with the binding domain of hERα, created a conformational 
change in the receptor, inducing its dimerization, thus, interrupting its down-
stream signaling as well as crosstalks [41]. The conformational change observed 
in the estrogen receptor upon interaction with the studied ligands will also impair 
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receptor activation. It is promising that these interactions with the sex hormone’s 
receptor, hERα with provoke breast cancer cell death, thus halting its progression to 
immortality [42].
5. Conclusion
The potential of the studied drug-like small molecules to inhibit estrogenic sig-
naling is a vital approach that should be exploited in the management of metastatic 
breast cancers.
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